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The 2012 Lasker-DeBakey Clinical Medical Research Award will be conferred on Thomas Starzl of
the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania, USA and Roy Calne of
theUniversity of Cambridge in Cambridge, UK. They are recognized for pioneering the development
of liver transplantation, an intervention that saves 20,000 lives world-wide each year.A Multitalented Organ
The liver is the largest solid organ in the
human body and performs a remarkably
diverse array of functions that are essential
for survival. It is the source of the vast
majority of abundant plasma proteins, in-
cluding blood clotting factors, albumin,
and other proteins that carry a variety of
lipophilic hormones in the plasma, lipo-
proteins that transport cholesterol and
triglycerides, and transferrin, which carries
iron in the ferric form (Fe3+). The liver also
plays a critical role in energy homeostasis,
receiving nearly all of the venous blood
drainage fromthe intestines, therebybeing
the first site receiving ingested nutrients
and playing a major role in both storing
absorbed carbohydrates in the form of
glycogen when energy balance is positive
and sustaining blood glucose levels via
gluconeogenesis when plasma glucose
levels are low. The liver is also responsible
for clearing or detoxifying diverse mole-
cules absorbed from the gut, such as
bacterial lipopolysaccharide (LPS), and
for metabolizing for elimination products
of catabolism in the systemic circulation.
As a result of these diverse and vital
functions, it is not surprising that acute
loss of liver function can lead to death
within days, with profuse hemorrhage,
profound hypotension, hypoglycemia,
and encephalopathy. Chronic liver dam-
age ultimately produces a similar set of
problems but has the additional compli-
cation that the normal liver architecture is
lost and replaced by fibrotic tissue (called
cirrhosis), requiring blood to bypass the
liver and resulting in dramatic shunting of
blood through vessels poorly suited to1096 Cell 150, September 14, 2012 ª2012 Elcarrying such large blood volumes. These
dilated vessels, called varices, are prone
to potentially fatal rupture. In addition,
the increased resistance to blood flow
through the liver leads to fluid accumula-
tion in the peritoneum (called ascites),
which frequently becomes infected.
Nonetheless, because there is consider-
able hepatic reserve and also remarkable
capacity of the liver to regenerate after
injury, many insults that cause damage
to the liver do not cause clinical signs or
symptoms, and these typically only
appearwhen less than 10%of normal liver
function remains.
The causes of liver failure are diverse
(Table 1), and understanding its etiology
has led to substantial progress in preven-
tion of liver failure, particularly among
infectious causes. Identification of the
Hepatitis B virus led to the virtual elimina-
tion of transmission by blood transfusion
and to development of an efficacious
vaccine. The Nobel Prize in Medicine
was awarded in 1976 to Baruch Blumberg
for the discovery of viral antigens that initi-
ated these developments. More recently,
identification of the Hepatitis C virus has
been followed by development of new
effective therapeutic regimens that can
eliminate this virus in a large fraction of
affected subjects (Jacobson et al., 2011;
Poordad et al., 2011). Despite these
advances, more than 700,000 people die
annually from liver failure, representing
a leading cause of global death.
Toward Transplantation
Unlike kidney failure, for which dialysis
can provide long-term replacement ofsevier Inc.normal kidney function, respiratory fail-
ure, which can be overcome by supple-
mental oxygen and ventilation, and heart
failure, which has a variety of pharmaco-
logic and mechanical assist devices that
can augment normal function, because
of the high diversity of liver functions,
there is presently no long-term ‘‘liver
replacement’’ therapy.Asaconsequence,
liver transplantation was recognized as
a potential therapy, with work beginning
in the 1950s. At that time, progress was
being made in both bone marrow and
kidney transplantation. The first success-
ful human kidney transplant had been
performed by Murray in 1954 at Brigham
and Women’s Hospital, and bone marrow
transplantation was achieved by Thomas
in 1956 at the Fred Hutchinson Cancer
Center. Murray and Thomas shared the
Nobel Prize in Medicine in 1990 for these
achievements. Efforts in orthotopic liver
transplantation began in parallel. Attemp-
ted liver transplantation in dogs was re-
ported by Staudacher in 1952, Welch in
1955, and Cannon in 1957 but encoun-
tered numerous obstacles, including pre-
servation of the harvested liver prior to
transplantation, management of the an-
hepatic state in the recipient, and chal-
lenges to the surgical connection of the
transplanted liver to its dual blood sup-
plies, venous drainage, and biliary system
(Figure 1). These early efforts produced
only short-term survival.
In addition to these hurdles, it was
recognized that immune rejection of
transplanted organs was a major compli-
cating factor; for this reason, Thomas and
Murray both did their initial transplants
Table 1. Causes of Liver Failure Leading
to Transplantation
Infectious Diseases
Hepatitis B virus
Hepatitis C virus
Nonviral Hepatic Inflammation
Nonalcoholic steatohepatitis
Autoimmune hepatitis
Primary sclerosing cholangitis
Primary biliary cirrhosis
Chemical/Drug Exposure
Ethanol
Acetaminophen
Other medications: antibiotics,
anticonvulsants, NSAIDs
Amatoxins from Amanita phalloides
mushroom
Herbal supplements: kava, ephedra,
skullcap, and pennyroyal
Industrial toxins: carbon tetrachloride,
vinyl chloride
Congenital Abnormalities/Genetic Diseases
Biliary atresia
Alagille syndrome
Alpha-1-antitrypsin deficiency
Wilson’s disease
Hereditary hemochromatosis
Tyrosinemia
Homozygous familial hypercholesterolemia
Glycogen storage diseases (Types I, IV)
Cancer
Hepatocellular carcinoma
Cholangiocarcinoma
Hepatoblastomabetween identical twins. These consider-
ations led to recognition that minimizing
the immune response to allografts would
be critical for transplantation to advance
in clinical practice. The discovery of the
antigens of the major histocompatibility
complex and their important role in trans-
plant rejection led to development of
methods for determining human leuco-
cyte antigen (HLA) types and matching
for major histocompatibility antigens.
This succeeded in reducing, but not elim-
inating, rejection of transplanted organs.
Interestingly, the liver ultimately proved
more tolerant of antigenic mismatch than
most other tissues, requiring only match-
ing of ABO blood type. Rejection none-
theless remained a major obstacle, which
led to recognition that pharmacologicinhibition of the immune response
would be an essential component of
transplantation.
Impact of Immunosuppression
Roy Calne, a surgeon at University of
Cambridge, made major contributions to
the development of effective clinical regi-
mens for immunosuppression. In 1951,
Elion and Hitchings at Burroughs Well-
come, who received the Nobel Prize in
Medicine in 1988, developed an inhibitor
of purine biosynthesis, 6-mercaptopurine
(6-MP), which proved to have potent
activity in the treatment of childhood
leukemia. Based on this observation,
Robert Schwartz at Tufts Medical School
in Boston subsequently demonstrated
the ability of 6-MP to reduce the immune
response. Calne picked up on these leads
and showed that 6-MP and subsequently
azathioprine, a prodrug also developed
by Elion and Hitchings, had the ability to
inhibit rejection of autologous kidney
transplants in dogs (Calne, 1960, 1961).
These developments had broad impact,
leading to effective regimens for trans-
plant of human kidneys among noniden-
tical twins, achieved in 1962, and also to
the first reports of extended survival with
liver transplant in dogs, reported in 1960
by Moore and colleagues at Brigham
and Women’s Hospital in Boston and
Starzl and colleagues at University of
Colorado in Denver (Moore et al., 1960;
Starlz et al., 1960).
Spurred by these successes, on March
1, 1963, Starzl and colleagues performed
the first human liver transplant in a child
with congenital biliary atresia and fol-
lowed this effort by two further transplants
in adult patients in May and June of the
same year (Starzl et al., 1963). Immuno-
suppression with azathioprine was used
in each case, with various adjunctive
interventions, including thymectomy, pre-
dnisone, and/or splenectomy. The first
patient died in surgery due to uncontrol-
lable hemorrhage, whereas the latter two
died from pulmonary embolism within
days of surgery. Similar failures elsewhere
curtailed efforts for several years until
improvements in surgical techniques,
donor organ procurement and preserva-
tion, and immunosuppressive regimens
were developed.
It was only in 1967 that Starzl per-
formed the first liver transplant that re-Cell 150, Sepsulted in survival of the recipient for
more than 12 months (Starzl et al., 1968).
Shortly thereafter, Calne and colleagues
performed the first liver transplant in
Europe (Calne and Williams, 1968). In the
years following, these two teams pio-
neered and perfected the techniques of
liver transplantation. This entailed pains-
taking efforts that often resulted in incre-
mental improvements in harvesting and
preservation of cadaveric donor livers,
surgical techniques of removal of the
diseased liver in patients with abnormal
vascularization patterns secondary to
portal hypertension and severe clotting
factor deficiency, and technical improve-
ments in reconstruction of the biliary tract
associated with the insertion of the
transplanted liver. Collectively, these
advances still achieved relatively low 1
year survival rates. Among 170 liver trans-
plants between 1967 and 1980, Starzl’s
team reported only a 30% 1 year survival
rate (Starzl et al., 1982). Calne’s series of
130 liver transplants between 1968 and
1983 achieved similar results (Rolles
et al., 1984). It was apparent that acute
and chronic rejection of the donor liver
by the host immune system remained
a major clinical problem that was limiting
the efficacy of liver transplantation.
From Experimental Treatment
to Widespread Use
The last critical advance that ultimately
changed the course of liver transplanta-
tion came with the development of
a new immunosuppressant, cyclosporine
A, which was discovered in 1972 at San-
doz. Cyclosporine A is a calcineurin inhib-
itor that decreases interleukin 2 (IL-2)
production and significantly suppresses
effector T cell function and associated
cytokine release. Calne and others ob-
tained extremely encouraging experi-
mental results using this new compound
in animal organ grafts, which was fol-
lowed shortly by introduction into human
transplantation (Calne et al., 1978, 1979).
Three years later, Starzl reported a
doubling of the 1 year survival rate of liver
transplant recipients to about 60% using
cyclosporine and prednisone for immuno-
suppression after liver transplantation
(Starzl et al., 1981).
Armed with these marked improve-
ments in survival, and with FDA approval
of cyclosporine for immunosuppressiontember 14, 2012 ª2012 Elsevier Inc. 1097
Figure 1. Orthotopic Liver Transplantation
The donor liver is shown in place after transplantation into the recipient.
Anastomoses occur between the native and donor hepatic artery (red), portal
vein (blue), inferior vena cava (blue), and common bile duct (green).for solid organ transplanta-
tion, a consensus meeting on
liver transplantation was con-
vened by the National Insti-
tutes of Health of the USA in
1983, which concluded that
this surgical procedure was
no longer experimental but
was a therapeutic option for
liver failure that was destined
to result in death. With this
logjam broken, liver trans-
plantation came into the
clinical armamentarium and
began being performed on a
much larger scale by far more
surgeons, many of whom
were trained by Starzl and
Calne.
From this beginning, liver
transplantation has been
established as a life-saving
treatment for liver failure. It is
estimated that 20,000 people
receive liver transplants each
year world-wide in several
hundred centers (WHO,
2008). Between January 1,1988 and April 30, 2012, 115,458 liver
transplants were performed in the USA
alone. The 1 year survival of a liver
transplant patient has improved to
85%–88%, and the 5 year survival is
74% (The U.S. Organ Procurement
and Transplantation Network and the
Scientific Registry of Transplant Recipi-
ents, 1997–2007, http://optn.transplant.
hrsa.gov/).
Improvements in liver transplantation
have continued. In 1994, tacrolimus
(FK506, also a calcineurin inhibitor) was
approved by the FDA for use in liver trans-
plantation and then extended to other
organ transplantations. Randomized
clinical trials have shown superiority of
tacrolimus over cyclosporine in prevent-
ing rejection and graft loss. Current
approaches commonly employ immuno-
suppression early after transplantation
with tacrolimus and glucocorticoids, fol-
lowed by tapering of steroid dosage in
the first 6 months posttransplantation.
Beyond this period, the immunosup-
pressive regimen is reduced to the
minimal doses required to prevent
chronic rejection, thereby minimizing the
risk of adverse effects. A number of new
immunosuppressive drugs have been1098 Cell 150, September 14, 2012 ª2012 Elintroduced, such as sirolimus (inhibitor
of mammalian target of rapamycin
[mTOR]), mycophenolate mofetil (inhibitor
of purine synthesis), IL-2-receptor-block-
ing antibody, and anti-CD3 monoclonal
antibody, which allow customization of
the immunosuppression regimen. Addi-
tionally, improved medical management
of patients prior to and after transplan-
tation, including new drugs for infectious
complications in transplant recipients,
has also contributed to improved
survival.
A Problem of Scarcity
Despite the striking success of liver trans-
plantation, its application remains limited
by organ availability. Thus, there are
more than 16,000 patients listed for liver
transplantation in the United States, but
only 5,000–6,000 liver transplants are per-
formed each year, and more than 2,000
people die annually while waiting for a
liver transplant. This has led to the
establishment of rigorous criteria for allo-
cation of donor livers. Patients with end-
stage liver disease are typically referred
for liver transplantation evaluation at the
time of their first decompensation.
Patients may be listed for transplantationsevier Inc.unless they have comorbid-
ities that make survival after
transplantation unlikely.
These include advanced
cardiopulmonary disease,
incurable extrahepatic malig-
nancy, and active alcohol or
substance abuse. Among
patients listed for transplant
who are an ABO blood type
match to the donor organ,
priority is given to patients
with the shortest expected
survival without transplanta-
tion, based on objective bio-
chemical measures of liver
and kidney function. Match-
ing of body size and vascular
anatomy of donor and recip-
ient are also critical in final
organ allocation.
The scarcity of donor
organs has prompted efforts
to develop living donor liver
transplantation (LDLT), taking
advantage of the liver’s
regenerative capacity. The
first successful LDLTwas per-formed in 1989 by Broelsch and
colleagues in a child with biliary atresia
at the University of Chicago. Living dona-
tion of the lateral segment of the left lobe
of the liver has become an accepted prac-
tice in pediatric transplantation, with
excellent donor and recipient outcomes.
The relatively small mass of the left
hepatic lobe, however, has limited the
utility of left lobe transplantation in adult
recipients.
Recognizing limitations inherent to
transplantation, efforts continue to
develop artificial extracorporeal liver
support. The Molecular Adsorbents Re-
circulating System (MARS), developed at
the University of Rostock in Germany
and clinically available since 2005, con-
sists of two separate dialysis circuits
that are capable of removing a number
of lipophilic, albumin-bound toxins, in-
cluding ammonia, bile acids, and bilirubin.
Though only of short-term utility, this
system can be used in cases of acute liver
failure as a bridge to transplantation.
Perspective
The work of Starzl and Calne in bringing
liver transplantation from inception to
a widely used life-saving procedure
represents a spectacular achievement
realized despite daunting obstacles and
years of failure in human experimentation
that offered scant promise of long-term
success. Their ultimate achievement
required remarkable innovation and
courage, melding surgical technique, the
basic science and pharmacology of
the immune system, and masterful
management of the highly complex and
dynamic physiology that results from
liver failure and its correction via trans-
plantation. The scientific underpinnings
of all of the elements involved in comple-
tion of a successful liver transplant
are truly staggering in their scope. In
addition to their innovating spirit, it is
worth contemplating the breadth of basic
and clinical disciplines that Starzl and
Calne had to command in order to bring
liver transplantation to practice. The re-
sulting benefit to patients provides
a compelling argument for the broad
training of physicians in basic and clinical
disciplines and for continued—andpatient—support for innovative work to
advance human health.REFERENCES
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